GSK-J4 Inhibition of KDM6B Histone Demethylase Blocks Adhesion of Mantle Cell Lymphoma Cells to Stromal Cells by Modulating NF-& kappa;B Signaling

Multiple signaling pathways facilitate the survival and drug resistance of malignant B-cells by regulating their migration and adhesion to microenvironmental niches. NF-?B pathways are commonly dysregulated in mantle cell lymphoma (MCL), but the exact underlying mechanisms are not well understood. Here, using a co-culture model system, we show that the adhesion of MCL cells to stromal cells is associated with elevated levels of KDM6B histone demethylase mRNA in adherent cells. The inhibition of KDM6B activity, using either a selective inhibitor (GSK-J4) or siRNA-mediated knockdown, reduces MCL adhesion to stromal cells. We showed that KDM6B is required both for the removal of repressive chromatin marks (H3K27me3) at the promoter region of NF-?B encoding genes and for inducing the expression of NF-?B genes in adherent MCL cells. GSK-J4 reduced protein levels of the RELA NF-?B subunit and impaired its nuclear localization. We further demonstrated that some adhesion-induced target genes require both induced NF-?B and KDM6B activity for their induction (e.g., IL-10 cytokine gene), while others require induction of NF-?B but not KDM6B (e.g., CCR7 chemokine gene). In conclusion, KDM6B induces the NF-?B pathway at different levels in MCL, thereby facilitating MCL cell adhesion, survival, and drug resistance. KDM6B represents a novel potential therapeutic target for MCL.

Automated summary

Multiple signaling pathways regulate the migration and adhesion of malignant B-cells, including the dysregulated NF-?B pathways in mantle cell lymphoma (MCL). Using a co-culture model system, it was found that KDM6B histone demethylase is associated with MCL cell adhesion to stromal cells. Inhibition of KDM6B reduces MCL adhesion and impairs the NF-?B pathway, suggesting KDM6B as a potential therapeutic target for MCL.